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Until very recently it was a difficult task to
treat fungous infections caused by dermato-
phytes. This was emphasized in a symposium
during which we stated that the response to
therapy is unsatisfactory in onychomycosis and
in tinca capitis due to illicrosporum audoulni or
to the large-spored cndothrix group of triehophy-
ton (1). With introduction of the oral fungistatic
agent, griscofulvin, this situation was changed
radically.
Griseofulvin is a fermentation product of sev-
eral types of penicillium, first described in 1939
by Oxford and colleagues (2), which has been
used as an antibiotic agent in plants. The work
of Gentles and colleagues (3, 4) and Martin (5),
who used this agent orally for experimental ring-
worm of guinea pigs, suggested its therapeutic
apphcation in tinea of the scalp caused by if.
audouini or T. tonsurans and in T. rubrum infec-
tions of the skin or nails which are resistant to
conventional therapy. These facts make thorough
mycological identification almost imperative
since the antibiotic has no effect on the genus
Candida. It may even aggravate a condition
caused by these organisms, as we observed in one
instance.
Griseofulvin was first used in man by Riehl
(6), who described its effectiveness in 15 patients
with dermatomycoses; complete recovery, with-
out local therapy, occurred rapidly. Williams and
colleagues (7) treated nine patients with T.
rubrum infection of the skin or nails. Within three
weeks there was relief from pruritus, reappear-
ance of normal perspiration on the palm, and rc-
growth of normal nail. The fungus became in-
creasingly difficult to find in scrapings.
Blank and Roth (8) administered 5000 mg.
daily to a patient with severe cutaneous T.
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rubrum granulomas. The excellent result encour-
aged further study among 31 patients with
dermatomycoscs who received 1000 to 2000 mg.
daily. Results were uniformly good after several
weeks. Some patients reported transient head-
aches or gastric distress during the first weeks of
treatment but the only significant side effect was
an urticaria-like reaction occurring in a patient
who had been treated for six wrecks.
Goldfarb and Rosenthal (9) reported on 17 pa-
tients treated for two to 12 weeks with griseo-
fulvin, 250 mg. daily in children and 750 to 1000
mg. daily in adults. In glabrous lesions, pruritus
usually ceased after four days of treatment,
erythcma was reduced after seven days, and in
palms infected with T. rubrum, normal perspira-
tion returned two to three weeks after treatment
was started. The positive cultures and smears
usually became negative in three weeks although
more time was required for hyperkeratotic palms
and soles. In T. rubrum of the nails, significant
improvement usually occurred in 12 weeks. Lab-
oratory studies in these patients revealed no
toxicity attributable to the drug. Transient
headaches were reported by seven patients, fleet-
ing pruritus occurred in two, and two patients
reported fatigue and diarrhea. A child who had
received 250 mg. daily for one week developed a
generalized maculopapular eruption which dis-
appeared when medication was discontinued hut
reappeared on resumption of therapy.
Robinson and colleagues (10) used griscofulvin
for 53 patients with tinea capitis, 24 with ony-
chomyosis, five with tinea eruris, 14 with tinea
corporis, and 18 with tinea pedis. In daily doses
of 25 mg./Kg. for children and 750 to 1000 mg.
for adults, it was markedly effective among this
series of patients. Cure was rapid, usually within
five weeks, in all indications except onychomy-
eosis, for which five months of treatment may be
required before complete eradication of fungi
occurs. Clinical observation and laboratory
studies showed that the drug is relatively non-
toxic.
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TABLE 1
Indications for yriseofulvin therapy in 44 patients
Indication •Intectiug Oeganism
Number
Patients
tinea capitis
tinea capitis
tinea capitis
tinea corporis
tinea pedis
onychomycosis
onychomycosis
Microsporum audouini
Microsporum canis
Trichophyton tonsurans
Trichophyton rubrnnt
Trichophyton mentag-
rophytes
Trichophyton rubruni
Trichophyton mentay-
rophytes
25)
1 31
5)
3
4
5)
6
1)
Goldman and colleagues (11) investigated the
factors of resistance and relapse among 46 pa-
tients who had received griseofulvin, with excel-
lent clinical results, for relatively long periods of
time. These authors concluded that true resist-
ance was never encountered although response
was slow in some patients. Relapse was observed
in two patients with T. rubrum infections of the
smooth skin.
METHOD
Griseofulvin* was used in 44 patients with
dermatomycoses (Table 1). All the patients with
tinea capitis were children; the dosage was 250
mg. griseofulvin twice daily. The adults with
tinea corporis and pedis or onychomycosis re-
ceived 500 mg. twice daily. The average length of
treatment was 45 days. No local therapy was used.
Identification of the infecting organism was
made by culture before therapy was begun.
Laboratory procedures, such as wet mounts,
examination of hair under Wood's lamp, and cul-
turing, were performed periodically during and
after therapy. Cure was considered to have oc-
curred after two consecutive negative cultures
were obtained at ten-day intervals. Blood counts,
urinalyses, and otber laboratory tests were per-
formed for all patients during therapy.
CLINICAL RESULTS
Tinea Capitis
The results of griseofulvin therapy in the 31
children are summarized in Table 2. Complete
clinical and laboratory cures occurred in all
eases in a mean of 45 days.
All patients with tinea eapitis were followed,
* Griseofulvin was supplied as Fulvicin by G.
Kenneth Hawkins, M.D. of the Division of Clinical
Research, Sehering Corporation, Bloomfield, New
Jersey.
some for as long as three and one-half months
after cessation of therapy. There were no re-
currences.
Tinea capitis caused by M. audouini. The 25
children with this condition were cured in a mean
of 44 days. During the first week, the character-
istic bright green fluorescence changed to a dull
bluish white. During the second week the fluores-
cence continued to diminish and by the fourth or
fifth week no fluorescence was detectable in the
hair shaft. Only the tips revealed a faint fluores-
cence. By the second or third week, some growth
of normal hair in the affected areas was observed.
Tinea capitis caused by III. canis. This patient
showed clinical and laboratory evidence of cure
after six weeks.
Tinea capitis caused by T. tonsurans. This in-
fection, in five patients, was cured in a mean of 53
days. The "black dots" gradually vanished and
normal growth of hair was observed during the
second or third week of therapy. This is note-
worthy in T. tonsurans infections since with the
old standard treatment often several months or
years elapsed before normal growth was observed.
Tinea Corporis and Tinea Pedis
Tinea corporis caused by T. rubrum. In these
three patients, pruritus diminished on the second
day of therapy and erythema on the third. The
first negative culture usually was obtained on the
tenth day. Despite the negative culture, stunted
myeelial elements could be found in the wet
mount.
Tinea pedis caused by T. mentayrophytes. These
four patients had localized vesicular lesions lim-
ited to the soles. Positive cultures were obtained
from the vesicles. Clinical improvement was
noticeable after 17 days of therapy, as evidenced
by drying of the vesieles, crust formations, and
scaliness. At this time cultures were still positive.
An additional 11 or 12 days were required before
negative cultures were obtained. At this time
mild erythema and moderate scaliness persisted.
Cultures were repeated at weekly intervals for
four weeks with negative results. Despite the
negative cultures, stunted mycelial elements
could be found in the wet mounts. Pruritus per-
sisted in one patient despite negative myeologie
and clinical findings.
Onychomycosis
In the five patients with T. rubrum infections,
some growth of healthy nail could be seen after
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FIG. 1. Microsporum audouini infected hair after two weeks treatment with Fulvicin. Long hyphae
partly thickened with hyphal fragmentation. Note the absence of the mosaic patterned microspores.
three weeks and in nine weeks one-third of the
nail was clinically normal. The palms were also
involved in two of these patients. The palmar
hyperkeratosis diminished at the same time that
scaliness subsided, which occurred after one
week. The previous pathological palmar anhy-
drosis gradually disappeared and normal per-
spiration was observed ten to 14 days after
therapy was begun. The one patient with T.
mentagrophytes responded similarly.
Side Effects
There were no untoward effects of therapy ex-
cept in one patient who reported transient gas-
tric distress. Examination of blood and urine and
studies of hepatic function yielded normal results
Infecting Organism
TABLE 2
Results of griseofulvin therapy (500 m. daily) in 31 children with tinea capitis
Microsporuln audouini
Micros porurn canis
Trichophyton tonsurans
Number of Patients
20 males,
5 females
1 male
4 males,
1 female
Summary
Duration of Duration of Weeks ofAge Disease in Therapy in Follow-upRange Months Days(Mean) (Mean) (Mean) (Mean)
212 112
(7) (3')
2174
(44)
212
(5'2)
10 2 42 4
5—11 1—8 36—75 2—8
(812) (4) (53) (5)
31
SideCured Effects
25 none
1 none
5 none
31 none2 12 1-12 21—75
(71) (312) (45)
2—12
(5)
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Fio. 2. Microsporum audouini infected hair after three weeks treatment with Fulvicin. Several hyphal
elements. A group of rectangular and roundish spores in a "tarse favique"-like arrangement.
from all patients The sperm count and 17-keto-
steroid level remained normal in a medical stu-
dent who had received griseofulvin for nine weeks.
MYCOLOGICAL OBSERVATIONS
As therapy progressed, certain mycologienl
changes of interest were observed.*
Al. audouini
After the second week, the morphological char-
acteristics of the fungi in the hair revealed tran-
sition from the typical microid mosaic pattern of
the spores to frequent formation of hyphal ele-
ments. This change was almost always observed
at the proximal end of the hair (Figure 1). Occa-
sionally, after the third week, these hyphae
showed rectangular fragmentation and groups of
irregularly sized, bizarrely shaped spores could be
seen. These were similar to those observed in T.
schoenleini infection of the hair (tarsc favique)
(Figure 2).
There was a decrease in the size of the cultures
* We gratefully acknowledge laboratory as-
sistance provided by Miss Dominica Furnari.
TABLE 3
Laboratory findings of hair in 25 children with
Micros porum audouini tinea capitis after
six weeks
Number of Patients
9
3
9
3
cultures
+
+
-+
Wet Mounts
-
-
-
-
Fluorescence
+
+
+
-
Total 25 15+
10—
25— 21+
4—
grown from specimens obtained at various times
as therapy progressed. At times such cultures
measured two to three mm. in diameter after one
week of treatment as compared with cultures more
than three times that size which had been grown
before patients were treated. However, the
stunted colonies did not show noticeable micro-
scopic alteration.
We attempted to reinfect a child who was un-
- C
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dergoing treatment—with a few greenish fluores-
cent and bluish fluorescent hairs. After a week of
close contact under an occlusive dressing, no in-
fection developed. It had been anticipated that
the griseofulvin content of the epidermis would
prevent a positive take.
The results of laboratory studies in the 25 chil-
dren with tinea capitis due to Iii. audoulni are
summarized in Table 3. Our studies indicate that
the presence or absence of fluorescence is not al-
ways indicative of the presence or absence of an
active infection. Also, 15 negative wet mounts
were associated with 15 positive cultures. The
fluorescence may not have been of the intense
yellowish type and in these instances cultures
generally were negative. On the other hand, it is
probable that repeated scrapings may have pro-
duced positive findings in the cases with negative
wet mounts.
We also found that when fungi could not be
cultured from faintly fluorescent hair tips, in
several instances positive cultures were obtained
from scrapings of the scalp.
T. tonsurans
As therapy advanced, the most remarkable
change was the transformation of the round endo-
spores into rectangular arthrospores; this oc-
curred between the second and third week. These
spores changed into irregularly shaped, bizarrely
outlined, occasionally distorted hyphae (Figure
3).
After six weeks of griseofulvin administration,
the cultures showed microscopic changes. The
colonies were yellowish, waxy, slow-growing, and
stunted. Due to the lack of actual mycelium, the
characteristic greenish fluorescence was absent or
present only minimally. These growths showed
abundant chiamydospores and the characteristic
piriform microconidia assumed an irregular
roundish shape (Figure 4).
Fie. 3. Trichophyton lonsurans infected hair after three weeks treatment with Fulvicin. Distorted
and curled hyphae with bizarre-shaped artbrospore-like elements.
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FIG. 4. Culture mount of a two week old culture of T. tonsurans from a hair after three weeks treat-
ment with Fulvicin. Note the abundance of chlamydospores, and the rounded microconidia. Note the
absence of piriform mierocouidia.
1)ISCUSSION
Griseofulvin is undoubtedly the most effective
antimyeotic agent available for the treatment of
superficial fungous infections caused by Micro-
sporum audouini, Trichophyton tonsurens, T.
rubrum and to a lesser degree in tinea caused by
T. mentagrophytes.
The mechanism of the therapeutic action of
griseofulvin is still obscure. According to studies
among our series of patients, it appears that some
type of eytotoxie action interferes with the via-
bility and normal development of dermatophytes.
The stunted growth and the distorted fungous
elements which are seen after a period of griseo-
fulvin administration indicate clearly that pro-
found metabolic disturbances occur in the fungi.
While there is little doubt that a rapid response
occurs in infections of the hair and skin, a longer
period of trial is required before the optimal dura-
tion and dosage factors can be determined for com -
pletc elimination of fungi from infected nails.
It is possible that improvement of tinea capitis
would require even less time if certain accessory
measures are performed, such as shaving the hair
immediately before dosage is initiated. In onycho-
mycosis, periodic trimming of the infected nail is
also desirable.
SUMMARY
Griseofulvin (Fulviein), 250 mg. twice daily,
was administered to 31 children with tinea capitis
due to Micros porum audouini, M. canis, or
Trichophyton tonsurans. In doses of 500 mg.
twice daily it was administered to three adults
with tinca corporis caused by T. rubrum, to four
adults with tinea pedis due to T. mentagrophytes,
and to six adults ivith onychomycosis from T.
rubrum or T. mentagrophytes.
The criterion for cure was two consecutive
negative cultures. This was usually obtained in
tinea eapitis in six to seven weeks and in tinea
corporis in five weeks. Major improvement in
onychomycosis occurred after 14 weeks. There
were no side effects of therapy.
Griscofulvin appears to be a significant ad-
vance in the management of superficial fungous
infections of the hair, skin, and nails.
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